Rebamipide CAS NO.90098-04-7

Anhui Haikang Pharmaceutical Co.,
Ltd. is a collection of scientific
research,production and sales
High-Tech Enterprise,which
established in 2009,and covers an
area of 28,000 ㎡.Company locates
in Anqing city,on the bond of
Yangtze River, invested 80 million
RMB to set up synthesis workshops
and clean workshops.All the
productions strictly conform to GMP
standard and equipped with
high-class R&D center.The first
branch was founded in 2010,called
Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.
Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.
To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Rebamipide, also known as rebamipide, is a new type of anti ulcer drug. It was first listed in Japan in 1990 as a drug for gastric ulcer and acute and chronic gastritis. Rebamipide is a gastric mucosal protective agent, which can increase gastric mucosal blood flow, prostaglandin E2 synthesis and gastric mucus secretion, and promote the expression of epidermal growth factor and its receptor, It can prevent ulcer and promote ulcer healing. It can promote the production of prostaglandins in gastric mucosa and protect gastric mucosa from the harm of various ulcer causing factors. It is suitable for the treatment of gastric ulcer, acute gastritis, acute exacerbation of chronic gastritis and gastric mucosal lesions, and has high clinical application value. Background: with the wide application of proton pump inhibitor (PPI) and the eradication of Helicobacter pylori infection as the main treatment of gastric ulcer, the clinical healing rate of peptic ulcer is as high as 80% - 90%, but the problem of ulcer recurrence still needs to be solved. In recent years, more and more attention has been paid to the relationship between ulcer healing quality and ulcer recurrence.

The chemical structure of Rebamipide contains the amide group at the para position of the benzyl group and the double bond at the 3 and 4 positions with the carbonyl group at the 2 position, which can dose-dependently inhibit the activation of neutrophils to produce reactive oxygen species, and can effectively eliminate them. Free radicals, thereby preventing free radicals from damaging the gastric mucosa. This product can also promote the synthesis of prostaglandins in the gastric mucosa and strengthen the gastric mucosal barrier. In addition, this product inhibits Hp's damage to gastric mucosa by preventing Helicobacter pylori (Hp) from adhering to gastric epithelial cells, reducing oxidative Chemicalbook stress, and reducing the concentration of cytokines produced by Helicobacter pylori. Animal experiments have shown that Rebamipide can scavenge free radicals in mucosal epithelial cells, and has a significant inhibitory effect on O2- produced by neutrophils. It also has a scavenging effect on hydroxyl free radicals and OH, which can inhibit the production of Hp and chemotactic factors. It can increase the synthesis of prostaglandin by inhibiting the damaging effect of bile acid on the gastric mucosa.